Rizatriptan - Drug Monograph | DrugInfoSys ODIS

Primary Characteristics

It is of Synthetic origin.

Non-proprietary name: Rizatriptan.

Pharmacokinetics

Absorption: Rizatriptan has an oral bioavailability is 23.5% (±23.5%), pre-systemic (first-pass) metabolism accounts for 73% (±2%).

Distribution: Rizatriptan has a plasma protein binding is 14%.

Indications

Rizatriptan is primarily indicated in conditions like Long-term treatment of reflux oesophagitis, Mild to moderate dementia in alzheimer's disease.

Contraindications

Rizatriptan is contraindicated in conditions like Peripheral vascular disease, Ischaemic heart disease, Cerebrovascular accident, Uncontrolled hypertension.

Dosage

Rizatriptan's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
7.5 mg	7.5 mg	Every 24h	PO	The maximum daily dose of rizatriptan is 30 mg each day. If other medications are taken in addition to rizatriptan, the maximum daily dosage may be lower.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

10 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Rizatriptan is known to cause more or less tolerable side effects which are usually transient. These include Asthenia , Blurred vision, Dizziness, Dyspepsia , Dyspnea, Fatigue, Flushing, Heaviness, Insomnia, Myalgia, Nervousness, Palpitation, Pruritus , Sensation of warmth, Sweating , Tachycardia, Thirst, Tingling , Tremor, Urticaria, Vertigo.

Warnings / Precautions

5HT1 agonists (e.g Rizatriptan) should be used with caution in conditions which predispose to coronary artery disease (pre-existing cardiac disease), pregnancy and breast-feeding. 5HT1 agonists are recommended as monotherapy and should not be taken concurrently with other acute migraine therapies. Little information is available on the use of these drugs in the elderly (over 65 year). Caution is also required in mild or moderate hepatic impairment and renal impairment; not to be taken until 24 hours after stopping ergotamine-type prepration (ergotamine-type prepration not to be taken until 6 hours after Rizatriptan)

Available Brands

None recorded.

Storage Conditions

Rizatriptan should be stored Tabs.

Drug Classification

1.7.1 — Acute migraine attack